Clinical Trials
2 trialsNCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00162500 2010-11-10
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Hadassah Medical Organization
Phase 2 Withdrawn